Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. View on euronews ...

The drugmaker said it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped the treatment.

Pfizer has decided to halt the development of its potential once-daily pill treatment for obesity due to safety concerns ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Meta c Mark Zuckerberg took the stand on Monday in a historic antitrust trial that could force the tech giant to break off ...

Experts say the tariffs are unlikely to bring back production of generic medicines, given their slim profit margins ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the most ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...